TrialClinical cancer research : an official journal of the American Association for Cancer Research2021

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

Georgina V Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.